Next Article in Journal
Antioxidant Effectiveness of Vegetable Powders on the Lipid and Protein Oxidative Stability of Cooked Turkey Meat Patties: Implications for Health
Next Article in Special Issue
Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
Previous Article in Journal
Vitamin C in Cultured Human (HeLa) Cells: Lack of Effect on DNA Protection and Repair
Previous Article in Special Issue

Dyslipidemia in Obesity: Mechanisms and Potential Targets

Department of Internal Medicine, Diabetes and Vascular Centre, Sint Franciscus Gasthuis, Rotterdam, P.O. Box 10900, 3004 BA, The Netherlands
Author to whom correspondence should be addressed.
Nutrients 2013, 5(4), 1218-1240;
Received: 21 December 2012 / Revised: 14 February 2013 / Accepted: 27 March 2013 / Published: 12 April 2013
(This article belongs to the Special Issue Dyslipidemia and Obesity)
Obesity has become a major worldwide health problem. In every single country in the world, the incidence of obesity is rising continuously and therefore, the associated morbidity, mortality and both medical and economical costs are expected to increase as well. The majority of these complications are related to co-morbid conditions that include coronary artery disease, hypertension, type 2 diabetes mellitus, respiratory disorders and dyslipidemia. Obesity increases cardiovascular risk through risk factors such as increased fasting plasma triglycerides, high LDL cholesterol, low HDL cholesterol, elevated blood glucose and insulin levels and high blood pressure. Novel lipid dependent, metabolic risk factors associated to obesity are the presence of the small dense LDL phenotype, postprandial hyperlipidemia with accumulation of atherogenic remnants and hepatic overproduction of apoB containing lipoproteins. All these lipid abnormalities are typical features of the metabolic syndrome and may be associated to a pro-inflammatory gradient which in part may originate in the adipose tissue itself and directly affect the endothelium. An important link between obesity, the metabolic syndrome and dyslipidemia, seems to be the development of insulin resistance in peripheral tissues leading to an enhanced hepatic flux of fatty acids from dietary sources, intravascular lipolysis and from adipose tissue resistant to the antilipolytic effects of insulin. The current review will focus on these aspects of lipid metabolism in obesity and potential interventions to treat the obesity related dyslipidemia. View Full-Text
Keywords: free fatty acid; postprandial lipemia; apolipoprotein B; non-HDL-C; small dense LDL; acylation-stimulation protein; statin; fibrate free fatty acid; postprandial lipemia; apolipoprotein B; non-HDL-C; small dense LDL; acylation-stimulation protein; statin; fibrate
Show Figures

Figure 1

MDPI and ACS Style

Klop, B.; Elte, J.W.F.; Cabezas, M.C. Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients 2013, 5, 1218-1240.

AMA Style

Klop B, Elte JWF, Cabezas MC. Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients. 2013; 5(4):1218-1240.

Chicago/Turabian Style

Klop, Boudewijn, Jan Willem F. Elte, and Manuel Castro Cabezas. 2013. "Dyslipidemia in Obesity: Mechanisms and Potential Targets" Nutrients 5, no. 4: 1218-1240.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop